Eiko LifeSciences Limited (EIKO) Fair Value & Analysis
Basic Materials · IN · Market cap ₹719M
Fair value as of: Jul 5, 2026
From 23 valuation models · updated today
Share price −3.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹48.79 – ₹64.80 · fair‑value band ₹39.96 – ₹66.60 · the ₹49.65 price screens below the ₹53.28 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Eiko LifeSciences Limited (EIKO) currently trades at ₹49.65, while our model-based Fair Value estimate is ₹53.28 — implying the stock looks roughly 7.3% undervalued today. We read business quality at 49/100 (below-average quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Eiko LifeSciences Limited generated revenue of ₹527M at a net margin of 8.5%. Revenue grew 62.7% year over year. It earns a return on equity of 8.4%. Net debt stands at ₹44.1M. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹39.96 (bear case) to ₹66.60 (bull case); at ₹49.65, the current price sits within that range. The share trades about 23% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -59% fair-value upside — at 7%, EIKO screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Eiko LifeSciences Limited manufactures and sells specialty and fine chemicals in India. The company operates through Specialty Chemicals; Pharma Intermidiates; Food Additives; Oleo Chemicals; and Cosmetic Ingredients segments. The company offers organic and inorganic specialty chemicals. Its products are used in pharmaceuticals, agrochemicals, aroma chemicals, electronic chemicals, etc. In addition, the company is involved in processing, formulating, producing, buying, selling, and exporting of specialty and fine chemicals. The company was formerly known as Narendra Investments (Delhi) Limited and changed its name to Eiko LifeSciences Limited in June 2021. Eiko LifeSciences Limited was incorporated in 1977 and is based in Thane, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Eiko LifeSciences Limited reported revenue of ₹527M in FY2026 versus ₹254M in FY2022, a compound +20.0%/yr. Reported net income was ₹45.0M in FY2026, compounding +58.9%/yr from FY2022.
Is EIKO fairly valued? → Check now
Similar stocks
10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | $516.71 | $221.55 | -57% |
| L'Air Liquide S.A AIQUY | $37.93 | $15.46 | -59% |
| Air Products and Chemicals, Inc A1PD34 | R$364.32 | R$50.60 | -86% |
| Intercontinental Exchange, Inc I1CE34 | R$359.64 | R$307.76 | -14% |
| Wanhua Chemical Group 600309 | ¥72.46 | ¥51.34 | -29% |
| Asian Paints Limited ASIANPAINT | ₹2,674 | ₹739.38 | -72% |
| Nan Ya Plastics Corporation 1303 | 96.90 TWD | 7.39 TWD | -92% |
| PPG Industries, Inc PPG | 1,988 MXN | 1,169 MXN | -41% |
| LyondellBasell Industries N.V L1YB34 | R$149.60 | R$46.85 | -69% |
| Solar Industries India Limited SOLARINDS | ₹18,441 | ₹4,083 | -78% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Eiko LifeSciences Limited (EIKO) undervalued?
What is the fair value of EIKO?
What is the quality score of EIKO?
What is the revenue of Eiko LifeSciences Limited (EIKO)?
What is the net profit margin of EIKO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.